This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Díaz-Aragón A, Fernández-Barros CL, Enciso-Muñoz JM, Ceballos-Reyes G, Gutiérrez-Salmeán G, León Hernández FJ, et al.e. Posicionamiento en torno al diag-nóstico y tratamiento de las dislipidemias. Rev Mex Cardiol. 2018; 29(3): 148-168.Díaz-AragónAFernández-BarrosCLEnciso-MuñozJMCeballos-ReyesGGutiérrez-SalmeánGLeónHernández FJet ale. Posicionamiento en torno al diag-nóstico y tratamiento de las dislipidemias2018293148168Search in Google Scholar
World Health Organization. Cardiovascular diseases (CVDs). [http://www.who.int/news-room/fact-sheets/detail/cardiovasculard-diseases-(cvds); accessed June 13 2020].World Health Organizationhttp://www.who.int/news-room/fact-sheets/detail/cardiovasculard-diseases-(cvds);accessed June 132020Search in Google Scholar
Barquera S, Pedroza-Tobías A, Medina C, Hernández-Barrera L, Bibbins-Domingo K, Lozano R, et al. Global overview of the epidemiology of atherosclerotic cardiovascular disease. Arch Med Res. 2015; 46(5): 328-338.BarqueraSPedroza-TobíasAMedinaCHernández-BarreraLBibbins-DomingoKLozanoRet alGlobal overview of the epidemiology of atherosclerotic cardiovascular disease201546532833810.1016/j.arcmed.2015.06.00626135634Search in Google Scholar
Nowbar AN, Gitto M, Howard JP, Francis DP, Al-Lamee R. Mortality from ischemic heart disease. Circ Cardiovasc Qual Outcomes. 2019; 12(6): e005375.NowbarANGittoMHowardJPFrancisDPAl-LameeRMortality from ischemic heart disease2019126e00537510.1161/CIRCOUTCOMES.118.005375661371631163980Search in Google Scholar
Martinez-Sanchez C, Borrayo G, Carrillo J, Juarez U, Quintanilla J, Jerjes-Sanchez C. Clinical management and hospital outcomes of acute coronary syndrome patients in Mexico: The Third National Registry of Acute Coronary Syndromes (RENASICA III). Arch Cardiol México. 2016; 86(3): 221-232.Martinez-SanchezCBorrayoGCarrilloJJuarezUQuintanillaJJerjes-SanchezCClinical management and hospital outcomes of acute coronary syndrome patients in Mexico: The Third National Registry of Acute Coronary Syndromes (RENASICA III)201686322123210.1016/j.acmx.2016.04.00727256475Search in Google Scholar
Canalizo-Miranda E, Favela-Pérez EA, Salas-Anaya JA, Gómez-Díaz R, Jara-Espino R, Del L, et al. Guía de práctica clínica Diagnóstico y tratamiento de las dislipidemias. Rev Med Inst Mex Seguro Soc. 2013; 51(6): 700-709.Canalizo-MirandaEFavela-PérezEASalas-AnayaJAGómez-DíazRJara-EspinoRDelLet alGuía de práctica clínica Diagnóstico y tratamiento de las dislipidemias2013516700709Search in Google Scholar
McEvoy JW, Whelton SP, Blumenthal RS. Dyslipidemia. In: Bakris GL, Sorrentino MJ, Editors. Hypertension: A Companion to Braunwald’s Heart Disease, 3rd ed. Chicago, IL, USA: Elsevier, 2018: 353-360.McEvoyJWWheltonSPBlumenthalRSDyslipidemiaInBakrisGLSorrentinoMJEditorsChicago, IL, USAElsevier2018353–36010.1016/B978-0-323-42973-3.00038-XSearch in Google Scholar
Hurtubise J, McLellan K, Durr K, Onasanya O, Nwabuko D, Ndisang JF. The different facets of dyslipidemia and hypertension in atherosclerosis. Curr Atheroscler Rep. [Internet] 2016; 18(12): 82.HurtubiseJMcLellanKDurrKOnasanyaONwabukoDNdisangJFThe different facets of dyslipidemia and hypertension in atherosclerosis201618128210.1007/s11883-016-0632-z27822682Search in Google Scholar
Matías-Pérez D, Pérez-Campos E, Antonio García-Montalvo I, Antonio I, Montalvo G. A genetic view of familial hypercholesterolemia. Nutr Hosp. 2015; 32(6): 2421-2426.Matías-PérezDPérez-CamposEAntonioGarcía-Montalvo IAntonioIMontalvoGA genetic view of familial hypercholesterolemia201532624212426Search in Google Scholar
Smith LC, Massey JB, Sparrow JT, Gotto AM, Pownall HJ. Structure and dynamics of human plasma lipoproteins. In: Bakris GL, Sorrentino MJ, Editors. Supramolecular Structure and Function. Boston, MA, USA: Springer US; 1983; 205-244.SmithLCMasseyJBSparrowJTGottoAMPownallHJStructure and dynamics of human plasma lipoproteinsInBakrisGLSorrentinoMJEditorsBoston, MA, USASpringer US;1983205–24410.1007/978-1-4684-4478-0_7Search in Google Scholar
Barter PJ, Brewer HB, Chapman MJ, Hennekens CH, Rader DJ, Tall AR. Cholesteryl ester transfer protein. Arterioscler Thromb Vasc Biol. 2003; 23(2): 160-167.BarterPJBrewerHBChapmanMJHennekensCHRaderDJTallARCholesteryl ester transfer protein200323216016710.1161/01.ATV.0000054658.91146.6412588754Search in Google Scholar
Yamashita T, Lakota K, Taniguchi T, Yoshizaki A, Sato S, Hong W, et al. An orally-active adiponectin receptor agonist mitigates cutaneous fibrosis, inflammation and microvascular pathology in a murine model of systemic sclerosis. Sci Rep. 2018; 8(1): 11843.YamashitaTLakotaKTaniguchiTYoshizakiASatoSHongWet alAn orally-active adiponectin receptor agonist mitigates cutaneous fibrosis, inflammation and microvascular pathology in a murine model of systemic sclerosis2018811184310.1038/s41598-018-29901-w608138630087356Search in Google Scholar
Huang Q, Qin L, Dai S, Zhang H, Pasula S, Zhou H, et al. AIP1 suppresses atherosclerosis by limiting hyperlipidemia-induced inflammation and vascular endothelial dysfunction. Arterioscler Thromb Vasc Biol. 2013; 33(4): 795-804.HuangQQinLDaiSZhangHPasulaSZhouHet alAIP1 suppresses atherosclerosis by limiting hyperlipidemia-induced inflammation and vascular endothelial dysfunction201333479580410.1161/ATVBAHA.113.301220363788523413429Search in Google Scholar
Kuivenhoven JA, Hegele RA. Mining the genome for lipid genes. Biochim Biophys Acta. 2014; 1842(10): 1993-2009.KuivenhovenJAHegeleRAMining the genome for lipid genes20141842101993200910.1016/j.bbadis.2014.04.02824798233Search in Google Scholar
Varret M, Rabès JP, Saint-Jore B, Cenarro A, Marinoni JC, Civeira F, et al. A third major locus for autosomal dominant hypercholesterolemia maps to 1p34.1-p32. Am J Hum Genet. 1999; 64(5): 1378-1387.VarretMRabèsJPSaint-JoreBCenarroAMarinoniJCCiveiraFet alA third major locus for autosomal dominant hypercholesterolemia maps to 1p34.1-p3219996451378138710.1086/302370137787410205269Search in Google Scholar
Akioyamen LE, Genest J, Shan SD, Reel RL, Albaum JM, Chu A, et al. Estimating the prevalence of heterozygous familial hypercholesterolaemia: A systematic review and meta-analysis. BMJ Open. 2017; 7(9): e016461.AkioyamenLEGenestJShanSDReelRLAlbaumJMChuAet alEstimating the prevalence of heterozygous familial hypercholesterolaemia: A systematic review and meta-analysis201779e01646110.1136/bmjopen-2017-016461558898828864697Search in Google Scholar
Nassoury N, Blasiole DA, Tebon Oler A, Benjannet S, Hamelin J, Poupon V, et al. The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR. Traffic. 2007; 8(6): 718-732.NassouryNBlasioleDATebonOler ABenjannetSHamelinJPouponVet alThe cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR20078671873210.1111/j.1600-0854.2007.00562.x17461796Search in Google Scholar
Luo Y, Warren L, Xia D, Jensen H, Sand T, Petras S, et al. Function and distribution of circulating human PCSK9 expressed extrahepatically in transgenic mice. J Lipid Res. 2009; 50(8): 1581-1588.LuoYWarrenLXiaDJensenHSandTPetrasSet alFunction and distribution of circulating human PCSK9 expressed extrahepatically in transgenic mice20095081581158810.1194/jlr.M800542-JLR200272404919060325Search in Google Scholar
Dijk W, Le May C, Cariou B. Beyond LDL: What role for PCSK9 in triglyceride-rich lipoprotein metabolism? Trends Endocrinol Metab. 2018; 29(6): 420-434.DijkWLeMay CCariouBBeyond LDL: What role for PCSK9 in triglyceride-rich lipoprotein metabolism?201829642043410.1016/j.tem.2018.03.01329665987Search in Google Scholar
Lalanne F, Lambert G, Amar MJA, Chétiveaux M, Zaïr Y, Jarnoux AL, et al. Wild-type PCSK9 inhibits LDL clearance but does not affect apoB-containing lipoprotein production in mouse and cultured cells. J Lipid Res. 2005; 46(6): 1312-1319.LalanneFLambertGAmarMJAChétiveauxMZaïrYJarnouxALet alWild-type PCSK9 inhibits LDL clearance but does not affect apoB-containing lipoprotein production in mouse and cultured cells20054661312131910.1194/jlr.M400396-JLR20015741654Search in Google Scholar
Seidah NG, Benjannet S, Wickham L, Marcinkiewicz J, Bélanger Jasmin S, Stifani S, et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): Liver regeneration and neuronal differentiation. Proc Natl Acad Sci USA. 2003; 100(3): 928-933.SeidahNGBenjannetSWickhamLMarcinkiewiczJBélangerJasmin SStifaniSet alThe secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): Liver regeneration and neuronal differentiation2003100392893310.1073/pnas.033550710029870312552133Search in Google Scholar
Gustafsen C, Kjolby M, Nyegaard M, Mattheisen M, Lundhede J, Buttenschøn H, et al. The hypercholesterolemia-risk gene SORT1 facilitates PCSK9 secretion. Cell Metab. 2014; 19(2): 310-318.GustafsenCKjolbyMNyegaardMMattheisenMLundhedeJButtenschønHet alThe hypercholesterolemia-risk gene SORT1 facilitates PCSK9 secretion201419231031810.1016/j.cmet.2013.12.00624506872Search in Google Scholar
Schmidt RJ, Beyer TP, Bensch WR, Qian YW, Lin A, Kowala M, et al. Secreted proprotein convertase subtilisin/ kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo. Biochem Biophys Res Commun. 2008; 370(4): 634-640.SchmidtRJBeyerTPBenschWRQianYWLinAKowalaMet alSecreted proprotein convertase subtilisin/ kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo2008370463464010.1016/j.bbrc.2008.04.00418406350Search in Google Scholar
Marian AJ. PCSK9 as a therapeutic target in atherosclerosis. Curr Atheroscler Rep. 2010; 12(3): 151-154.MarianAJPCSK9 as a therapeutic target in atherosclerosis201012315115410.1007/s11883-010-0099-220425252Search in Google Scholar
Seidah NG. PCSK9 as a therapeutic target of dyslipidemia. Expert Opin Ther Targets. 2009; 13(1): 19-28.SeidahNGPCSK9 as a therapeutic target of dyslipidemia2009131192810.1517/1472822080260071519063703Search in Google Scholar
Sabatine MS. Proprotein convertase subtilisin/ kexin type 9 (PCSK9) inhibitors: Comparing and contrasting guidance across the Atlantic. Eur Heart J. 2017; 38(29): 2256-2258.SabatineMSProprotein convertase subtilisin/ kexin type 9 (PCSK9) inhibitors: Comparing and contrasting guidance across the Atlantic201738292256225810.1093/eurheartj/ehw57228110294Search in Google Scholar
Li S, Zhang Y, Xu R-X, Guo Y-L, Zhu C-G, Wu N-Q, et al. Proprotein convertase subtilisin-kexin type 9 as a biomarker for the severity of coronary artery disease. Ann Med. 2015; 47(5): 386-393.LiSZhangYXuR-XGuoY-LZhuC-GWuN-Qet alProprotein convertase subtilisin-kexin type 9 as a biomarker for the severity of coronary artery disease201547538639310.3109/07853890.2015.104290826153823Search in Google Scholar
Alonso R, Mata P, Muñiz O, Fuentes-Jimenez F, Díaz JL, Zambón D, et al. PCSK9 and lipoprotein (a) levels are two predictors of coronary artery calcification in asymptomatic patients with familial hypercholesterolemia. Atherosclerosis. 2016; 254: 249-253.AlonsoRMataPMuñizOFuentes-JimenezFDíazJL,ZambónDet alPCSK9 and lipoprotein (a) levels are two predictors of coronary artery calcification in asymptomatic patients with familial hypercholesterolemia201625424925310.1016/j.atherosclerosis.2016.08.03827594539Search in Google Scholar
Kim JH. Letter: Serum levels of PCSK9 are associated with coronary angiographic severity in patients with acute coronary syndrome (Diabetes Metab J. 2018;42:207-14). Diabetes Metab J. 2018; 42(4): 348-349.KimJHLetter: Serum levels of PCSK9 are associated with coronary angiographic severity in patients with acute coronary syndrome (Diabetes Metab J201842434834910.4093/dmj.2018.0135610735530136453Search in Google Scholar
Tang Z, Li T, Peng J, Zheng J, Li T, Liu L, et al. PCSK9: A novel inflammation modulator in atherosclerosis? J Cell Physiol. 2019;234(3): 2345-2355.TangZLiTPengJZhengJLiTLiuLet alPCSK9: A novel inflammation modulator in atherosclerosis?201923432345235510.1002/jcp.2725430246446Search in Google Scholar
Hopkins PN, Defesche J, Fouchier SW, Bruckert E, Luc G, Cariou B, et al. Characterization of autosomal dominant hypercholesterolemia caused by PCSK9 cain of function mutations and its specific treatment with alirocumab, a PCSK9 monoclonal antibody. Circ Cardiovasc Genet. 2015; 8(6): 823-831.HopkinsPNDefescheJFouchierSWBruckertELucGCariouBet alCharacterization of autosomal dominant hypercholesterolemia caused by PCSK9 cain of function mutations and its specific treatment with alirocumab, a PCSK9 monoclonal antibody20158682383110.1161/CIRCGENETICS.115.001129509846626374825Search in Google Scholar
Cohen J, Pertsemlidis A, Kotowski IK, Graham R, Garcia CK, Hobbs HH. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet. 2005; 37(2): 161-165.CohenJPertsemlidisAKotowskiIKGrahamRGarciaCKHobbsHHLow LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9200537216116510.1038/ng150915654334Search in Google Scholar
Miyake Y, Kimura R, Kokubo Y, Okayama A, Tomoike H, Yamamura T, et al. Genetic variants in PCSK9 in the Japanese population: Rare genetic variants in PCSK9 might collectively contribute to plasma LDL cholesterol levels in the general population. Atherosclerosis. 2008; 196(1): 29-36.MiyakeYKimuraRKokuboYOkayamaATomoikeHYamamuraTet alGenetic variants in PCSK9 in the Japanese population: Rare genetic variants in PCSK9 might collectively contribute to plasma LDL cholesterol levels in the general population20081961293610.1016/j.atherosclerosis.2006.12.03517316651Search in Google Scholar
Zhao Z, Tuakli-Wosornu Y, Lagace TA, Kinch L, Grishin NV, Horton JD, et al. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet. 2006; 79(3): 514-523.ZhaoZTuakli-WosornuYLagaceTAKinchLGrishinNVHortonJDet alMolecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote200679351452310.1086/507488155953216909389Search in Google Scholar
Abifadel M, Varret M, Rabès J-P, Allard D, Ouguerram K, Devillers M, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003; 34(2): 154-156.AbifadelMVarretMRabèsJ-PAllardDOuguerramKDevillersMet alMutations in PCSK9 cause autosomal dominant hypercholesterolemia200334215415610.1038/ng116112730697Search in Google Scholar
Timms KM, Wagner S, Samuels ME, Forbey K, Goldfine H, Jammalapati S, et al. A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree. Hum Genet. 2004; 114(4): 349-353.TimmsKMWagnerSSamuelsMEForbeyKGoldfineHJammalapatiSet alA mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree2004114434935310.1007/s00439-003-1071-914727179Search in Google Scholar
Hunt SC, Hopkins PN, Bulka K, McDermott MT, Thorne TL, Wardell BB, et al. Genetic localization to chromosome 1p32 of the third locus for familial hypercholesterolemia in a Utah kindred. Arterioscler Thromb Vasc Biol. 2000; 20(4): 1089-1093.HuntSCHopkinsPNBulkaKMcDermottMTThorneTLWardellBBet alGenetic localization to chromosome 1p32 of the third locus for familial hypercholesterolemia in a Utah kindred20002041089109310.1161/01.ATV.20.4.108910764678Search in Google Scholar
Leren TP. Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia. Clin Genet. 2004; (4): 419-422.LerenTPMutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia20044419–42210.1111/j.0009-9163.2004.0238.x15099351Search in Google Scholar
Sun XM, Eden ER, Tosi I, Neuwirth CK, Wile D, Naoumova RP, et al. Evidence for effect of mutant PCSK9 on apolipoprotein B secretion as the cause of unusually severe dominant hypercholesterolaemia. Hum Mol Genet. 2005; 14(9): 1161-1169.SunXMEdenERTosiINeuwirthCKWileDNaoumovaRPet alEvidence for effect of mutant PCSK9 on apolipoprotein B secretion as the cause of unusually severe dominant hypercholesterolaemia20051491161116910.1093/hmg/ddi12815772090Search in Google Scholar
Bourbon M, Alves AC, Medeiros AM, Silva S, Soutar AK. Familial hypercholesterolaemia in Portugal. Atherosclerosis. 2008; 196(2): 633-642.BourbonMAlvesACMedeirosAMSilvaSSoutarAKFamilial hypercholesterolaemia in Portugal2008196263364210.1016/j.atherosclerosis.2007.07.01917765246Search in Google Scholar
Allard D, Amsellem S, Abifadel M, Trillard M, Devillers M, Luc G, et al. Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia. Hum Mutat. 2005; 26(5): 497.AllardDAmsellemSAbifadelMTrillardMDevillersMLucGet alNovel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia200526549710.1002/humu.938316211558Search in Google Scholar
Homer VM, Marais AD, Charlton F, Laurie AD, Hurndell N, Scott R, et al. Identification and characterization of two non-secreted PCSK9 mutants associated with familial hypercholesterolemia in cohorts from New Zealand and South Africa. Atherosclerosis. 2008; 196(2): 659-666.HomerVMMaraisADCharltonFLaurieADHurndellNScottRet alIdentification and characterization of two non-secreted PCSK9 mutants associated with familial hypercholesterolemia in cohorts from New Zealand and South Africa2008196265966610.1016/j.atherosclerosis.2007.07.02217765244Search in Google Scholar
Abifadel M, Rabès J-P, Devillers M, Munnich A, Erlich D, Junien C, et al. Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease. Hum Mutat. 2009; 30(4): 520-529.AbifadelMRabèsJ-PDevillersMMunnichAErlichDJunienCet alMutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease200930452052910.1002/humu.2088219191301Search in Google Scholar
Iacocca MA, Wang J, Sarkar S, Dron JS, Lagace T, McIntyre AD, et al. Whole-gene duplication of PCSK9 as a novel genetic mechanism for severe familial hypercholesterolemia. Can J Cardiol. 2018; 34(10): 1316-1324.IacoccaMAWangJSarkarSDronJSLagaceTMcIntyreADet alWhole-gene duplication of PCSK9 as a novel genetic mechanism for severe familial hypercholesterolemia201834101316132410.1016/j.cjca.2018.07.479Search in Google Scholar
Zambrano T, Hirata MH, Cerda Á, Dorea EL, Pinto GA, Gusukuma MC, et al. Impact of 3’UTR genetic variants in PCSK9 and LDLR genes on plasma lipid traits and response to atorvastatin in Brazilian subjects: A pilot study. Int J Clin Exp Med. 2015; 8(4): 5978-5988.ZambranoTHirataMHCerdaÁDoreaELPintoGAGusukumaMCet alImpact of 3’UTR genetic variants in PCSK9 and LDLR genes on plasma lipid traits and response to atorvastatin in Brazilian subjects: A pilot study20158459785988Search in Google Scholar
Robles-Osorio L, Huerta-Zepeda A, Ordóñez ML, Canizales-Quinteros S, Díaz-Villaseñor A, Gutiérrez-Aguilar R, et al. Genetic heterogeneity of autosomal dominant hypercholesterolemia in Mexico. Arch Med Res. 2006; 37(1): 102-108.Robles-OsorioLHuerta-ZepedaAOrdóñezMLCanizales-QuinterosSDíaz-VillaseñorAGutiérrez-AguilarRet alGenetic heterogeneity of autosomal dominant hypercholesterolemia in Mexico200637110210810.1016/j.arcmed.2005.04.018Search in Google Scholar
Mehta R, Zubirán R, Martagón AJ, Vazquez-Cárdenas A, Segura-Kato Y, Tusié-Luna MT, et al. The panorama of familial hypercholesterolemia in Latin America: A systematic review. J Lipid Res. 2016; 57(12): 2115-2129.MehtaRZubiránRMartagónAJVazquez-CárdenasASegura-KatoYTusié-LunaMTet alThe panorama of familial hypercholesterolemia in Latin America: A systematic review201657122115212910.1194/jlr.R072231Search in Google Scholar
Garg A, Fazio S, Duell PB, Baass A, Udata C, Joh T, et al. Molecular characterization of familial hypercholesterolemia in a North American cohort. J Endocr Soc. 2020; 4(1): 1-16.GargAFazioSDuellPBBaassAUdataCJohTet alMolecular characterization of familial hypercholesterolemia in a North American cohort20204111610.1210/jendso/bvz015Search in Google Scholar
Sánchez-Hernández RM, Tugores A, Nóvoa FJ, Brito-Casillas Y, Expósito-Montesdeoca AB, Garay P, et al. The island of Gran Canaria: A genetic isolate for familial hypercholesterolemia. J Clin Lipidol. 2019; 13(4): 618-626.Sánchez-HernándezRMTugoresANóvoaFJBrito-CasillasYExpósito-MontesdeocaABGarayPet alThe island of Gran Canaria: A genetic isolate for familial hypercholesterolemia201913461862610.1016/j.jacl.2019.04.099Search in Google Scholar
Abifadel M, Rabès JP, Jambart S, Halaby G, Gannagé-Yared MH, Sarkis A, et al. The molecular basis of familial hypercholesterolemia in Lebanon: Spectrum of LDLR mutations and role of PCSK9 as a modifier gene. Hum Mutat. 2009;30(7): E682-E691.AbifadelMRabèsJPJambartSHalabyGGannagé-YaredMHSarkisAet alThe molecular basis of familial hypercholesterolemia in Lebanon: Spectrum of LDLR mutations and role of PCSK9 as a modifier gene2009307E682E69110.1002/humu.21002Search in Google Scholar
Yang KC, Su YN, Shew JY, Yang KY, Tseng WK, Wu CC, et al. LDLR and ApoB are major genetic causes of autosomal dominant hypercholesterolemia in a taiwanese population. J Formos Med Assoc. 2007; 106(10): 799-807.YangKCSuYNShewJYYangKYTsengWKWuCCet alLDLR and ApoB are major genetic causes of autosomal dominant hypercholesterolemia in a taiwanese population20071061079980710.1016/S0929-6646(08)60044-3Search in Google Scholar
Pisciotta L, Oliva CP, Cefalù AB, Noto D, Bel-locchio A, Fresa R, et al. Additive effect of mutations in LDLR and PCSK9 genes on the phenotype of familial hypercholesterolemia. Atherosclerosis. 2006; 186(2): 433-440.PisciottaLOlivaCPCefalùABNotoDBel-locchioAFresaRet alAdditive effect of mutations in LDLR and PCSK9 genes on the phenotype of familial hypercholesterolemia2006186243344010.1016/j.atherosclerosis.2005.08.01516183066Search in Google Scholar
Noguchi T, Katsuda S, Kawashiri M-A, Tada H, Nohara A, Inazu A, et al. The E32K variant of PCSK9 exacerbates the phenotype of familial hypercholesterolaemia by increasing PCSK9 function and concentration in the circulation. Atherosclerosis. 2010; 210(1): 166-172.NoguchiTKatsudaSKawashiriM-ATadaHNoharaAInazuAet alThe E32K variant of PCSK9 exacerbates the phenotype of familial hypercholesterolaemia by increasing PCSK9 function and concentration in the circulation2010210116617210.1016/j.atherosclerosis.2009.11.01820006333Search in Google Scholar
Roche-Molina M, Sanz-Rosa D, Cruz FM, García-Prieto J, López S, Abia R, et al. Induction of sustained hypercholesterolemia by single adeno-associated virus-mediated gene transfer of mutant hPCSK9. Arterioscler Thromb Vasc Biol. 2015; 35(1): 50-59.Roche-MolinaMSanz-RosaDCruzFMGarcía-PrietoJLópezSAbiaRet alInduction of sustained hypercholesterolemia by single adeno-associated virus-mediated gene transfer of mutant hPCSK92015351505910.1161/ATVBAHA.114.30361725341796Search in Google Scholar
Bjørklund MM, Hollensen AK, Hagensen MK, Dagnæs-Hansen F, Christoffersen C, Mikkelsen JG, et al. Induction of atherosclerosis in mice and hamsters without germline genetic engineering. Circ Res. 2014; 114(11): 1684-1689.BjørklundMMHollensenAKHagensenMKDagnæs-HansenFChristoffersenCMikkelsenJGet alInduction of atherosclerosis in mice and hamsters without germline genetic engineering2014114111684168910.1161/CIRCRESAHA.114.30293724677271Search in Google Scholar
Goettsch C, Hutcheson JD, Hagita S, Rogers MA, Creager MD, Pham T, et al. A single injection of gain-of-function mutant PCSK9 adeno-associated virus vector induces cardiovascular calcification in mice with no genetic modification. Atherosclerosis. 2016; 251: 109-118.GoettschCHutchesonJDHagitaSRogersMACreagerMDPhamTet alA single injection of gain-of-function mutant PCSK9 adeno-associated virus vector induces cardiovascular calcification in mice with no genetic modification201625110911810.1016/j.atherosclerosis.2016.06.011498324627318830Search in Google Scholar
Denis M, Marcinkiewicz J, Zaid A, Gauthier D, Poirier S, Lazure C, et al. Gene inactivation of proprotein convertase subtilisin/kexin type 9 reduces atherosclerosis in mice. Circulation. 2012; 125(7): 894-901.DenisMMarcinkiewiczJZaidAGauthierDPoirierSLazureCet alGene inactivation of proprotein convertase subtilisin/kexin type 9 reduces atherosclerosis in mice2012125789490110.1161/CIRCULATIONAHA.111.05740622261195Search in Google Scholar
Al-Mashhadi RH, Sørensen CB, Kragh PM, Christoffersen C, Mortensen MB, Tolbod LP, et al. Familial hypercholesterolemia and atherosclerosis in cloned minipigs created by DNA transposition of a human PCSK9 gain-of-function mutant. Sci Transl Med. 2013; 5(166): 1-10.Al-MashhadiRHSørensenCBKraghPMChristoffersenCMortensenMBTolbodLPet alFamilial hypercholesterolemia and atherosclerosis in cloned minipigs created by DNA transposition of a human PCSK9 gain-of-function mutant2013516611010.1126/scitranslmed.300485323283366Search in Google Scholar
Hedayat AF, Park K-H, Kwon T-G, Woollard JR, Jiang K, Carlson DF, et al. Peripheral vascular atherosclerosis in a novel PCSK9 gain-of-function mutant Ossabaw miniature pig model. Transl Res. 2018; 192: 30-45.HedayatAFParkK-HKwonT-GWoollardJRJiangKCarlsonDFet alPeripheral vascular atherosclerosis in a novel PCSK9 gain-of-function mutant Ossabaw miniature pig model2018192304510.1016/j.trsl.2017.10.007581134329175268Search in Google Scholar
Miller M, Kwiterovich PO. Isolated low HDL-cholesterol as an important risk factor for coronary heart disease. Eur Heart J. 1990; 11(suppl H): 9-14.MillerMKwiterovichPOIsolated low HDL-cholesterol as an important risk factor for coronary heart disease199011suppl H91410.1093/eurheartj/11.suppl_H.92073916Search in Google Scholar
Puntoni M, Sbrana F, Bigazzi F, Sampietro T. Tangier disease: Epidemiology, pathophysiology, and management. Am J Cardiovasc Drugs. 2012; 12(5): 303-311.PuntoniMSbranaFBigazziFSampietroTTangier disease: Epidemiology, pathophysiology, and management201212530331110.1007/BF03261839Search in Google Scholar
Savel J, Lafitte M, Pucheu Y, Pradeau V, Tabarin A, Couffinhal T. Very low levels of HDL cholesterol and atherosclerosis, a variable relationship--a review of LCAT deficiency. Vasc Health Risk Manag. 2012; 8: 357-361.SavelJLafitteMPucheuYPradeauVTabarinACouffinhalTVery low levels of HDL cholesterol and atherosclerosis, a variable relationship--a review of LCAT deficiency2012835736110.2147/VHRM.S29985337331622701329Search in Google Scholar
Yuan F, Guo L, Park KH, Woollard JR, Taek-Geun K, Jiang K, et al. Ossabaw pigs with a PCSK9 fain-of-function mutation develop accelerated coronary atherosclerotic lesions: A novel model for preclinical studies. J Am Heart Assoc. 2018; 7(6): e006207.YuanFGuoLParkKHWoollardJRTaek-GeunKJiangKet alOssabaw pigs with a PCSK9 fain-of-function mutation develop accelerated coronary atherosclerotic lesions: A novel model for preclinical studies201876e00620710.1161/JAHA.117.006207590753329572319Search in Google Scholar
Duff CJ, Hooper NM. PCSK9: An emerging target for treatment of hypercholesterolemia. Expert Opin Ther Targets. 2011; 15(2): 157-168.DuffCJHooperNMPCSK9: An emerging target for treatment of hypercholesterolemia201115215716810.1517/14728222.2011.54748021204732Search in Google Scholar
Soria LF, Ludwig EH, Clarke HR, Vega GL, Grundy SM, McCarthy BJ. Association between a specific apolipoprotein B mutation and familial defective apolipoprotein B-100. Proc Natl Acad Sci USA. 1989; 86(2): 587-591.SoriaLFLudwigEHClarkeHRVegaGLGrundySMMcCarthyBJAssociation between a specific apolipoprotein B mutation and familial defective apolipoprotein B-100198986258759110.1073/pnas.86.2.587Search in Google Scholar
Myant NB. Familial defective apolipoprotein B-100: A review, including some comparisons with familial hypercholesterolaemia. Atherosclerosis. 1993; 104(12): 1-18.MyantNBFamilial defective apolipoprotein B-100: A review, including some comparisons with familial hypercholesterolaemia19931041211810.1016/0021-9150(93)90171-PSearch in Google Scholar
Dugaiczyk A, Haron JA, Stone EM, Dennison OE, Rothblum KN, Schwartz RJ. Cloning and sequencing of a deoxyribonucleic acid copy of glyceraldehyde-3-phosphate dehydrogenase messenger ribonucleic acid isolated from chicken muscle. Biochemistry. 1983; 22(7): 1605-1613.DugaiczykAHaronJAStoneEMDennisonOERothblumKNSchwartzRJCloning and sequencing of a deoxyribonucleic acid copy of glyceraldehyde-3-phosphate dehydrogenase messenger ribonucleic acid isolated from chicken muscle19832271605161310.1021/bi00276a0136303388Search in Google Scholar
Eden ER, Naoumova RP, Burden JJ, McCarthy MI, Soutar AK. Use of homozygosity mapping to identify a region on chromosome 1 bearing a defective gene that causes autosomal recessive homozygous hypercholesterolemia in two unrelated families. Am J Hum Genet. 200; 68(3): 653-660.EdenERNaoumovaRPBurdenJJMcCarthyMISoutarAKUse of homozygosity mapping to identify a region on chromosome 1 bearing a defective gene that causes autosomal recessive homozygous hypercholesterolemia in two unrelated families20068365366010.1086/318795127447811179013Search in Google Scholar
Soutar AK, Naoumova RP, Traub LM. Genetics, clinical phenotype, and molecular cell biology of auto-somal recessive hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2003; 23(11): 1963-1970.SoutarAKNaoumovaRPTraubLMGenetics, clinical phenotype, and molecular cell biology of auto-somal recessive hypercholesterolemia200323111963197010.1161/01.ATV.0000094410.66558.9A12958046Search in Google Scholar
Canizales-Quinteros S, Aguilar-Salinas CA, Huertas-Vázquez A, Ordóñez-Sánchez ML, Rodríguez-Torres M, Venturas-Gallegos JL, et al. A novel ARH splice site mutation in a Mexican kindred with autosomal recessive hypercholesterolemia. Hum Genet. 2005; 116(1-2): 114-120.Canizales-QuinterosSAguilar-SalinasCAHuertas-VázquezAOrdóñez-SánchezMLRodríguez-TorresMVenturas-GallegosJLet alA novel ARH splice site mutation in a Mexican kindred with autosomal recessive hypercholesterolemia20051161-211412010.1007/s00439-004-1192-915599766Search in Google Scholar
Harada K, Miyamoto Y, Morisaki H, Ohta N, Yamanaka I, Kokubo Y, et al. A novel Thr56Met mutation of the autosomal recessive hypercholesterolemia gene associated with hypercholesterolemia. J Atheroscler Thromb. 2010; 17(2): 131-140.HaradaKMiyamotoYMorisakiHOhtaNYamanakaIKokuboYet alA novel Thr56Met mutation of the autosomal recessive hypercholesterolemia gene associated with hypercholesterolemia201017213114010.5551/jat.287320124734Search in Google Scholar
Awan Z, Choi HY, Stitziel N, Ruel I, Bamimore MA, Husa R, et al. APOE p.Leu167del mutation in familial hypercholesterolemia. Atherosclerosis. 2013; 231(2): 218-222.AwanZChoiHYStitzielNRuelIBamimoreMAHusaRet alAPOE p.Leu167del mutation in familial hypercholesterolemia2013231221822210.1016/j.atherosclerosis.2013.09.00724267230Search in Google Scholar
Sharifi M, Futema M, Nair D, Humphries SE. Polygenic hypercholesterolemia and cardiovascular disease risk. Curr Cardiol Rep. 2019; 21(6): 43.SharifiMFutemaMNairDHumphriesSEPolygenic hypercholesterolemia and cardiovascular disease risk20192164310.1007/s11886-019-1130-z647700431011892Search in Google Scholar
Stoll M, Dell’Oca N. Genética de la hipercolesterolemia familiar. Rev Urug Cardiol. 2019; 34(3): 324-332.StollMDell’OcaNGenética de la hipercolesterolemia familiar2019343324332Search in Google Scholar
Bourbon M, Alves AC, Sijbrands EJ. Low-density lipoprotein receptor mutational analysis in diagnosis of familial hypercholesterolemia. Curr Opin Lipidol. 2017; 8(2): 120-129.BourbonMAlvesACSijbrandsEJLow-density lipoprotein receptor mutational analysis in diagnosis of familial hypercholesterolemia20178212012910.1097/MOL.000000000000040428169869Search in Google Scholar
Graham CA, McIlhatton BP, Kirk CW, Beattie ED, Lyttle K, Hart P, et al. Genetic screening protocol for familial hypercholesterolemia which includes splicing defects gives an improved mutation detection rate. Atherosclerosis. 2005; 182(2): 331-340.GrahamCAMcIlhattonBPKirkCWBeattieEDLyttleKHartPet alGenetic screening protocol for familial hypercholesterolemia which includes splicing defects gives an improved mutation detection rate2005182233134010.1016/j.atherosclerosis.2005.02.016Search in Google Scholar
Nose D, Hori M, Miyamoto Y, Imaizumi S, Harada-Shiba M, Saku K, et al. Discontinuation of LDL apheresis with evolocumab in an FH patient with a duplication of exon 2-6 in the LDLR gene. J Cardiol Cases. 2019; 19(2): 55-58.NoseDHoriMMiyamotoYImaizumiSHarada-ShibaMSakuKet alDiscontinuation of LDL apheresis with evolocumab in an FH patient with a duplication of exon 2-6 in the LDLR gene2019192555810.1016/j.jccase.2018.10.005Search in Google Scholar
Cheng S, Wu Y, Wen W, An M, Gao Y, Wang L, et al. Independent severe cases of heterozygous familial hypercholesterolemia caused by the W483X and novel W483G mutations in the low-density lipoprotein receptor gene that were clinically diagnosed as homozygous cases. Genet Test Mol Biomarkers. 2019; 23(6): 401-408.ChengSWuYWenWAnMGaoYWangLet alIndependent severe cases of heterozygous familial hypercholesterolemia caused by the W483X and novel W483G mutations in the low-density lipoprotein receptor gene that were clinically diagnosed as homozygous cases201923640140810.1089/gtmb.2019.0012Search in Google Scholar
Goldstein JL, Schrott HG, Hazzard WR, Bierman EL, Motulsky AG. Hyperlipidemia in Coronary Heart Disease II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest. 1973; 52(7): 1544-1568.GoldsteinJLSchrottHGHazzardWRBiermanELMotulskyAGHyperlipidemia in Coronary Heart Disease II19735271544156810.1172/JCI107332Search in Google Scholar
Berge KE, Tian H, Graf GA, Yu L, Grishin NV, Schultz J, et al. Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science. 2000; 290(5497): 1771-1775.BergeKETianHGrafGAYuLGrishinNVSchultzJet alAccumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters200029054971771177510.1126/science.290.5497.1771Search in Google Scholar
Rios J, Stein E, Shendure J, Hobbs HH, Cohen JC. Identification by whole-genome resequencing of gene defect responsible for severe hypercholesterolemia. Hum Mol Genet. 2010; 19(22): 4313-4318.RiosJSteinEShendureJHobbsHHCohenJCIdentification by whole-genome resequencing of gene defect responsible for severe hypercholesterolemia201019224313431810.1093/hmg/ddq352Search in Google Scholar
Lee MH, Lu K, Hazard S, Yu H, Shulenin S, Hidaka H, et al. Identification of a gene, ABCG5, important in the regulation of dietary cholesterol absorption. Nat Genet. 2001; 27(1): 79-83.LeeMHLuKHazardSYuHShuleninSHidakaHet alIdentification of a gene, ABCG5, important in the regulation of dietary cholesterol absorption2001271798310.1038/83799Search in Google Scholar
Soumian S, Albrecht C, Davies AH, Gibbs RG. ABCA1 and atherosclerosis. Vasc Med. 2005; 10(2): 109-119.SoumianSAlbrechtCDaviesAHGibbsRGABCA1 and atherosclerosis200510210911910.1191/1358863x05vm593raSearch in Google Scholar
Olson MV. Human genetic individuality. Annu Rev Genomics Hum Genet. 2012; 13: 1-27.OlsonMVHuman genetic individuality20121312710.1146/annurev-genom-090711-163825Search in Google Scholar
Ho Hong S, Rhyne J, Zeller K, Miller M. Novel ABCA1 compound variant associated with HDL cholesterol deficiency. Biochim Biophys Acta. 2002; 1587(1): 60-64.HoHong SRhyneJZellerKMillerMNovel ABCA1 compound variant associated with HDL cholesterol deficiency200215871606410.1016/S0925-4439(02)00066-2Search in Google Scholar
Ahmadzadeh A, Azizi F. Genes Associated with low serum high-density lipoprotein cholesterol. Arch Iran Med. 2014; 17(6): 444-450.AhmadzadehAAziziFGenes Associated with low serum high-density lipoprotein cholesterol2014176444450Search in Google Scholar
Sabatine MS. PCSK9 inhibitors: Clinical evidence and implementation. Nat Rev Cardiol. 2019; 16(3): 155-165.SabatineMSPCSK9 inhibitors: Clinical evidence and implementation201916315516510.1038/s41569-018-0107-830420622Search in Google Scholar